BWX Technologies (NYSE:BWXT) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

BWX Technologies (NYSE:BWXT) announced its quarterly earnings results on Monday. The technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.03, FiscalAI reports. BWX Technologies had a net margin of 10.11% and a return on equity of 31.34%. The firm had revenue of $901.62 million during the quarter, compared to analyst estimates of $902.41 million. During the same period in the previous year, the business posted $1.02 earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. BWX Technologies updated its FY 2026 guidance to 4.700-4.800 EPS.

Here are the key takeaways from BWX Technologies’ conference call:

• Strong quarterly results and raised guidance: Second-quarter revenue rose 18%, adjusted EBITDA increased 7%, and adjusted EPS grew 5%. BWXT raised its 2026 adjusted EBITDA guidance to $662 million–$672 million, EPS guidance to $4.70–$4.80, and free cash flow guidance to $345 million–$360 million.
• Robust demand and backlog growth: Backlog reached $8.4 billion, up 40% year over year, with a trailing-12-month book-to-bill ratio of 1.7x. Management said it expects a credible opportunity to secure at least one new-build nuclear equipment order before year-end.
• Portfolio simplification and strategic focus: BWXT agreed to sell more than 80% of its medical and stable-isotope enrichment businesses to Nordic Capital for $750 million upfront and up to $800 million, while retaining a 20% minority stake. The transaction is intended to focus capital and management resources on national security and commercial nuclear power.
• Commercial nuclear capacity investments will weigh on near-term margins: Commercial Operations revenue grew 72% and adjusted EBITDA more than doubled, but 2026 segment margin guidance was reduced to approximately 13% from 14% as BWXT invests in U.S. capacity, PCG integration, Canadian operations, and additional executive talent.
• Long-term growth opportunities are expanding: The company cited support from U.S. and Canadian nuclear initiatives, a more consistent U.S. aircraft-carrier procurement cadence, advanced nuclear fuel milestones, and potential mPower licensing and manufacturing agreements. BWXT also expects to decide soon on a deep-water U.S. commercial manufacturing site to produce large reactor components.

BWX Technologies Stock Performance

Shares of NYSE BWXT traded down $1.76 during midday trading on Wednesday, hitting $170.64. 220,698 shares of the company’s stock were exchanged, compared to its average volume of 1,016,502. The firm has a market cap of $15.63 billion, a P/E ratio of 45.63, a PEG ratio of 2.96 and a beta of 0.76. The stock’s 50 day moving average price is $186.82 and its 200-day moving average price is $201.30. BWX Technologies has a twelve month low of $157.10 and a twelve month high of $241.82. The company has a debt-to-equity ratio of 1.58, a current ratio of 2.40 and a quick ratio of 2.33.

BWX Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.27 per share. The ex-dividend date is Tuesday, August 18th. This represents a $1.08 annualized dividend and a dividend yield of 0.6%. BWX Technologies’s dividend payout ratio is currently 28.88%.

Wall Street Analysts Forecast Growth

BWXT has been the topic of several recent analyst reports. Seaport Research Partners upgraded BWX Technologies from a “neutral” rating to a “buy” rating and set a $245.00 price target on the stock in a report on Monday, June 22nd. Zacks Research lowered shares of BWX Technologies from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Wall Street Zen raised shares of BWX Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Truist Financial lifted their target price on BWX Technologies from $205.00 to $212.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. started coverage on shares of BWX Technologies in a research note on Monday, July 27th. They issued an “overweight” rating and a $230.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $228.20.

Key Headlines Impacting BWX Technologies

Here are the key news stories impacting BWX Technologies this week:

• Positive Sentiment: Raised outlook and solid Q2 execution: BWXT reported second-quarter adjusted EPS of $1.07, ahead of the $1.04 consensus, while revenue increased 18% year over year to approximately $902 million. Management raised 2026 EPS guidance to $4.70-$4.80 and free-cash-flow guidance to $345-$360 million. BWXT Q2 Earnings Call Centers on Higher Outlook and Nuclear Focus
• Positive Sentiment: Medical business sale sharpens the nuclear focus: BWXT agreed to sell its medical business and Kinectrics’ stable medical isotopes operations to Nordic Capital in a transaction valued at up to $800 million. BWXT will retain a minority stake, while proceeds can support commercial nuclear capacity, small modular reactor opportunities and defense programs. BWXT sells medical business for USD800 million
• Positive Sentiment: Long-term demand remains supportive: Commercial operations revenue surged 72% year over year in Q2, and total backlog reached roughly $8.39 billion, up from $6.01 billion a year earlier. The growth reflects expanding demand for nuclear components and supports longer-term revenue visibility.
• Positive Sentiment: Analyst support: BTIG reaffirmed a Buy rating and a $235 price target. Northland Securities raised its FY2026 EPS estimate to $4.71 from $4.68 and FY2027 to $5.17 from $5.11, above the broader current-year consensus of $4.61. BTIG rating update
• Neutral Sentiment: Mixed quarterly estimates: Northland lowered its Q3 2026 EPS forecast to $1.18 from $1.22 but increased its Q4 estimate to $1.34 from $1.33, leaving its full-year forecast higher at $4.71.
• Negative Sentiment: Valuation and execution risks: BWXT trades at a relatively high earnings multiple, while the medical divestiture, Precision Components Group integration and expansion of nuclear manufacturing capacity create execution risks. Commercial reactor projects may also face lengthy regulatory and deployment timelines.

Insider Activity at BWX Technologies

In related news, CFO Michael Thomas Fitzgerald sold 2,417 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $209.25, for a total value of $505,757.25. Following the transaction, the chief financial officer owned 6,884 shares in the company, valued at approximately $1,440,477. This represents a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Rex D. Geveden sold 10,000 shares of BWX Technologies stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $204.81, for a total value of $2,048,100.00. Following the sale, the chief executive officer directly owned 202,491 shares in the company, valued at $41,472,181.71. The trade was a 4.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BWX Technologies

Several large investors have recently modified their holdings of the stock. Wedbush Securities Inc. lifted its holdings in shares of BWX Technologies by 4.3% during the 4th quarter. Wedbush Securities Inc. now owns 1,263 shares of the technology company’s stock worth $218,000 after acquiring an additional 52 shares during the period. Guggenheim Capital LLC raised its stake in shares of BWX Technologies by 2.2% in the fourth quarter. Guggenheim Capital LLC now owns 2,598 shares of the technology company’s stock valued at $449,000 after buying an additional 55 shares during the period. Corient Private Wealth LLC boosted its stake in BWX Technologies by 1.2% in the 2nd quarter. Corient Private Wealth LLC now owns 5,880 shares of the technology company’s stock worth $847,000 after purchasing an additional 69 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in shares of BWX Technologies by 1.0% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 9,331 shares of the technology company’s stock worth $1,613,000 after buying an additional 88 shares in the last quarter. Finally, AlTi Global Inc. lifted its position in BWX Technologies by 1.6% during the fourth quarter. AlTi Global Inc. now owns 5,884 shares of the technology company’s stock valued at $1,017,000 after purchasing an additional 90 shares during the last quarter. 94.39% of the stock is owned by institutional investors.

About BWX Technologies

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.